Healing Co Inc.

2022 Q1 Form 10-Q Financial Statement

#000147793222001015 Filed on February 22, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021 Q3

Balance Sheet

Concept 2022 Q1 2021 Q4 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $224.9K $1.115M $0.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $207.0K
Receivables
Other Receivables
Total Short-Term Assets $464.4K $1.115M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $8.318K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $127.4K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $464.4K $1.115M
Total Long-Term Assets $127.4K $0.00
Total Assets $591.8K $1.115M $0.00
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.033M $1.827M $306.1K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.033M $1.827M $306.1K
Total Long-Term Liabilities
Total Liabilities $1.033M $1.827M $306.1K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$2.145M -$1.406M -$350.1K
YoY Change
Common Stock $44.01K $44.00K $44.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$441.4K -$712.4K -$878.5K
YoY Change
Total Liabilities & Shareholders Equity $591.8K $1.115M $0.00
YoY Change

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44000000 shares
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1115065 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
0 USD
CY2021Q4 us-gaap Assets
Assets
1115065 USD
CY2021Q2 us-gaap Assets
Assets
0 USD
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
135028 USD
CY2021Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
79110 USD
CY2021Q4 thcc Accounts Payable And Accrued Expenses Related Parties Current
AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
65000 USD
CY2021Q2 thcc Accounts Payable And Accrued Expenses Related Parties Current
AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
0 USD
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
627420 USD
CY2021Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
203615 USD
CY2021Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
1000000 USD
CY2021Q2 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
0 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1827448 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
282725 USD
CY2021Q4 us-gaap Liabilities
Liabilities
1827448 USD
CY2021Q2 us-gaap Liabilities
Liabilities
282725 USD
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 thcc Preferred Stock Designated Shares
PreferredStockDesignatedShares
5000000 shares
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
325000 shares
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
325 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1115065 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 USD
us-gaap Management Fee Expense
ManagementFeeExpense
154380 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
649675 USD
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1406383 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-326725 USD
CY2021Q4 us-gaap Professional Fees
ProfessionalFees
301763 USD
CY2020Q4 us-gaap Management Fee Expense
ManagementFeeExpense
0 USD
CY2020Q4 us-gaap Professional Fees
ProfessionalFees
2350 USD
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44000000 shares
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
44000 USD
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
44000 USD
us-gaap Professional Fees
ProfessionalFees
891402 USD
us-gaap Professional Fees
ProfessionalFees
4828 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-712383 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-282725 USD
CY2021Q4 us-gaap Management Fee Expense
ManagementFeeExpense
154380 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1115065 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
0 USD
CY2021Q4 us-gaap Revenues
Revenues
0 USD
CY2020Q4 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
CY2021Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27740 USD
CY2020Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
683 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33876 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3195 USD
us-gaap Management Fee Expense
ManagementFeeExpense
0 USD
CY2021Q4 us-gaap Operating Expenses
OperatingExpenses
483883 USD
CY2020Q4 us-gaap Operating Expenses
OperatingExpenses
3033 USD
us-gaap Operating Expenses
OperatingExpenses
1079658 USD
us-gaap Operating Expenses
OperatingExpenses
8023 USD
CY2021Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-483883 USD
CY2020Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3033 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1079658 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8023 USD
CY2021Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-483883 USD
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-3033 USD
us-gaap Net Income Loss
NetIncomeLoss
-1079658 USD
us-gaap Net Income Loss
NetIncomeLoss
-8023 USD
CY2021Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
CY2021Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44000000 shares
CY2020Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44000000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44000000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44000000 shares
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-282725 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-878500 USD
CY2021Q4 thcc Issuance Of Seed Preferred Stock For Cash Amount
IssuanceOfSeedPreferredStockForCashAmount
650000 USD
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-483883 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-169378 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-174368 USD
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-3033 USD
us-gaap Net Income Loss
NetIncomeLoss
-1079658 USD
us-gaap Net Income Loss
NetIncomeLoss
-8023 USD
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
55918 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-177401 USD
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-6355 USD
thcc Increasedecreaseinaccounts Payable And Accrued Expenses Related Party
IncreasedecreaseinaccountsPayableAndAccruedExpensesRelatedParty
65000 USD
thcc Increasedecreaseinaccounts Payable And Accrued Expenses Related Party
IncreasedecreaseinaccountsPayableAndAccruedExpensesRelatedParty
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1000000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
41260 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14378 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
650000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
14980 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
423805 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1073805 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14980 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1115065 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
602 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1347 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1115065 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1949 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">USE OF ESTIMATES - The preparation of the financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1115065 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1827448 USD
CY2021Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
1000000 USD
CY2021Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
8350000 USD
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
325000 shares

Files In Submission

Name View Source Status
0001477932-22-001015-index-headers.html Edgar Link pending
0001477932-22-001015-index.html Edgar Link pending
0001477932-22-001015.txt Edgar Link pending
0001477932-22-001015-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
thcc-20211231.xsd Edgar Link pending
thcc-20211231_cal.xml Edgar Link unprocessable
thcc-20211231_def.xml Edgar Link unprocessable
thcc-20211231_lab.xml Edgar Link unprocessable
thcc-20211231_pre.xml Edgar Link unprocessable
thcc_10q.htm Edgar Link pending
thcc_10qimg8.jpg Edgar Link pending
thcc_10q_htm.xml Edgar Link completed
thcc_ex1010.htm Edgar Link pending
thcc_ex1010img10.jpg Edgar Link pending
thcc_ex1010img11.jpg Edgar Link pending
thcc_ex1010img9.jpg Edgar Link pending
thcc_ex1011.htm Edgar Link pending
thcc_ex1011img6.jpg Edgar Link pending
thcc_ex1011img7.jpg Edgar Link pending
thcc_ex103.htm Edgar Link pending
thcc_ex104.htm Edgar Link pending
thcc_ex104img3.jpg Edgar Link pending
thcc_ex104img4.jpg Edgar Link pending
thcc_ex104img5.jpg Edgar Link pending
thcc_ex105.htm Edgar Link pending
thcc_ex105img7.jpg Edgar Link pending
thcc_ex105img9.jpg Edgar Link pending
thcc_ex106.htm Edgar Link pending
thcc_ex106img5.jpg Edgar Link pending
thcc_ex106img6.jpg Edgar Link pending
thcc_ex107.htm Edgar Link pending
thcc_ex107img15.jpg Edgar Link pending
thcc_ex107img16.jpg Edgar Link pending
thcc_ex108.htm Edgar Link pending
thcc_ex108img3.jpg Edgar Link pending
thcc_ex108img4.jpg Edgar Link pending
thcc_ex108img5.jpg Edgar Link pending
thcc_ex108img7.jpg Edgar Link pending
thcc_ex311.htm Edgar Link pending
thcc_ex312.htm Edgar Link pending
thcc_ex321.htm Edgar Link pending
thcc_ex322.htm Edgar Link pending